Botryosphaeran, a (1 → 3)(1 → 6)-β-D-glucan, reduces tumor development and cachexia syndrome in obese male rats by increasing insulin sensitivity and FOXO3a activity

Geraldelli, Danielli; Ribeiro, Mariana Costa; Medeiros, Tulio Couto; Comiran, Patrícia K.; Martins, Kamila Ortega; Oliveira, Matheus Fernandes de; Oliveira, Gabriela Araújo; Dekker, Robert F. H.; Barbosa-Dekker, Aneli M.; Alegranci, Pâmela; Queiroz, Eveline Aparecida Isquierdo Fonseca de

doi:10.1016/j.ijbiomac.2020.09.168

Cited by 14 publications

(17 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Botryosphaeran is produced by the ascomyceteous fungus Botryosphaeria rhodina MAMB‐05 under submerged fermentation conditions, 17 and several beneficial pharmacological activities have been described 18 . Previous studies from our research group have additionally demonstrated that botryosphaeran has significant anti‐obesogenic activity, 19 anti‐proliferative and pro‐apoptotic activity against breast carcinoma cells (MCF‐7), 20 and antitumour activity in Walker‐256 tumour‐bearing obese and non‐obese rats 21‐23 …”

Section: Introductionmentioning

confidence: 80%

“…The characterization of obesity and the analysis of tumour development were as described by Geraldelli et al 22 Samples of tumour, adipose tissue, liver, spleen and small intestine were collected by dissection, washed with isotonic saline solution, and kept frozen at À80 C until required for analysis.…”

Section: Animals and Experimental Protocolmentioning

confidence: 99%

“…18 Previous studies from our research group have additionally demonstrated that botryosphaeran has significant anti-obesogenic activity, 19 anti-proliferative and proapoptotic activity against breast carcinoma cells (MCF-7), 20 and antitumour activity in Walker-256 tumour-bearing obese and non-obese rats. [21][22][23] Geraldelli et al 22,23 demonstrated that botryosphaeran, at a dose of 30 mg/kg/d for 15 days, presented a significant antitumour and anti-cachetic effect in Walker-256 tumour-bearing obese and nonobese rats. The mechanism associated, at least in part, is with the beneficial metabolic effects of botryosphaeran in reducing the accumulation of adipose tissue and improving insulin sensitivity, as well as increasing apoptosis of tumour cells.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Antioxidant, anti‐inflammatory and beneficial metabolic effects of botryosphaeran [(1→3)(1→6)‐β‐d‐glucan] are responsible for its anti‐tumour activity in experimental non‐obese and obese rats bearing Walker‐256 tumours

Silva

Geraldelli

Martins

et al. 2022

Cell Biochemistry & Function

Self Cite

View full text Add to dashboard Cite

Botryosphaeran, a (1!3)(1!6)-β-D-glucan, presents several beneficial activities, such as antiproliferative, hypoglycemic and antitumoural activities. This study evaluated the effects of botryosphaeran on oxidative stress, inflammation and metabolic activities in Walker-256 tumour-bearing non-obese and obese rats. Wistars rats were divided into four groups: control tumour (CT); control tumour + botryosphaeran (CTB); obese tumour (OT), and obese tumour + botryosphaeran (OTB). In ninth week, obese and non-obese rats were inoculated with 1 Â 10 7 Walker-256 tumour cells and treated with botryosphaeran (30 mg/kg/d for 15 days). In 11th week, the following parameters were evaluated glycogen, glucose and lactate levels, pro-oxidant (TBARS) and antioxidant markers (superoxide dismutase [SOD]; catalase [CAT]; glutathione-S-transferase [GST]; reduced glutathione [GSH]; vitamin C) and cytokines. Obesity presented oxidative stress and inflammation, as demonstrated by high levels of TBARS, SOD and TNF-α, and lower levels of CAT, GSH and interleukin-10 (IL-10). Botryosphaeran significantly decreased TBARS and TNF-α and increased GST, GSH, vitamin C and IL-10 in the liver; increased SOD and vitamin C in tumour tissue; decreased TBARS in adipose tissue, and notably decreased the levels of glycogen and lactate in the tumour of CTB rats. Botryosphaeran promoted significant antioxidant, anti-inflammatory, and beneficial metabolic effects in Walker-256 tumour-bearing non-obese and obese rats, which contributed to its antitumour activity.

show abstract

Section: Introductionmentioning

confidence: 80%

Section: Animals and Experimental Protocolmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antioxidant, anti‐inflammatory and beneficial metabolic effects of botryosphaeran [(1→3)(1→6)‐β‐d‐glucan] are responsible for its anti‐tumour activity in experimental non‐obese and obese rats bearing Walker‐256 tumours

Silva

Geraldelli

Martins

et al. 2022

Cell Biochemistry & Function

Self Cite

View full text Add to dashboard Cite

show abstract

“…The glucan botryosphaeria significantly reduced tumor growth, body-weight loss and cachexia in obesity rats inoculated with Walker-256 tumor cells. Such treatment decreased mesenteric fat and insulin resistance, corrected macrocytic anemia, and increased FOXO3A activity [210].…”

Section: New Insightsmentioning

confidence: 97%

Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism

Schirrmacher¹

2020

Biomedicines

View full text Add to dashboard Cite

Mitochondria are of great relevance to health, and their dysregulation is associated with major chronic diseases. Research on mitochondria—156 brand new publications from 2019 and 2020—have contributed to this review. Mitochondria have been fundamental for the evolution of complex organisms. As important and semi-autonomous organelles in cells, they can adapt their function to the needs of the respective organ. They can program their function to energy supply (e.g., to keep heart muscle cells going, life-long) or to metabolism (e.g., to support hepatocytes and liver function). The capacity of mitochondria to re-program between different options is important for all cell types that are capable of changing between a resting state and cell proliferation, such as stem cells and immune cells. Major chronic diseases are characterized by mitochondrial dysregulation. This will be exemplified by cardiovascular diseases, metabolic syndrome, neurodegenerative diseases, immune system disorders, and cancer. New strategies for intervention in chronic diseases will be presented. The tumor microenvironment can be considered a battlefield between cancer and immune defense, competing for energy supply and metabolism. Cancer cachexia is considered as a final stage of cancer progression. Nevertheless, the review will present an example of complete remission of cachexia via immune cell transfer. These findings should encourage studies along the lines of mitochondria, energy supply, and metabolism.

show abstract

“…In Eastern world, mushrooms are widely used as medical and nutritional support in cancer patients, in order to improve fatigue and cachexia and to increase tolerability to chemotherapy. In fact, numerous animal and human studies have shown remarkable activity against a wide variety of tumors [22,23]. In the oncological field, β-glucans can stimulate the innate and adaptive immune response, inhibit the proliferation of cancer cells, promote apoptosis and block the angiogenesis [24][25][26].…”

Section: Introductionmentioning

confidence: 99%

Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review

Cognigni

Ranallo

Tronconi

et al. 2021

Exploration of Targeted Anti-Tumor Therapy

View full text Add to dashboard Cite

Fungal compounds have long been used for centuries as food supplements. β-glucans have been identified as the most interesting molecules with beneficial effects in several chronic diseases. In vitro studies have shown that they are able to elicit the immune cells maturation and activation with the result of an increased release of proinflammatory cytokines and chemokines and a stimulation of anti-bacterial activity of macrophages and neutrophils. As β-glucans enhance pathogen elimination through non-self antigens identification, they can also direct immune response against tumor cells. These compounds also stimulate the activity on adaptive immune cells and they have been regarded as biological response modifiers. In this way, β-glucans can be exploited as adjuvant cancer therapy, in particular by a synergic action with chemotherapy or immunotherapy. In the immuno-oncology era, the need is to identify innovative drugs that can simultaneously target and inhibit different biological processes relevant for cancer cells survivors. Recent clinical studies showed promising results about the combination of β-glucans and immune checkpoint inhibitors for patients affected by different solid tumors. This review aims to investigate molecular mechanisms of action of β-glucans and is focused on their application in clinical practice as immune-adjuvants for treatment of cancer patients.

show abstract

Botryosphaeran, a (1 → 3)(1 → 6)-β-D-glucan, reduces tumor development and cachexia syndrome in obese male rats by increasing insulin sensitivity and FOXO3a activity

Cited by 14 publications

References 46 publications

Antioxidant, anti‐inflammatory and beneficial metabolic effects of botryosphaeran [(1→3)(1→6)‐β‐d‐glucan] are responsible for its anti‐tumour activity in experimental non‐obese and obese rats bearing Walker‐256 tumours

Antioxidant, anti‐inflammatory and beneficial metabolic effects of botryosphaeran [(1→3)(1→6)‐β‐d‐glucan] are responsible for its anti‐tumour activity in experimental non‐obese and obese rats bearing Walker‐256 tumours

Mitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism

Potential benefit of β-glucans as adjuvant therapy in immuno-oncology: a review

Contact Info

Product

Resources

About